

Ozcan Yildiz


Prezzo del pacchetto da
$1,200Confronta i migliori medici di Cancro della cistifellea e i prezzi in Turchia. Trova qui la tua scelta ideale.
Selezioneremo i migliori medici in base alle tue esigenze e al tuo budget.
Revisionato medicalmente da Fahad Mawlood
Editor medico e Data ScientistMedici top
45
Turchia
Recensioni
14000+
Da pazienti reali
Ricevi piani di trattamento personalizzati gratuiti e scegli l'opzione migliore. Nessun impegno · Nessun costo per i nostri servizi




Prezzo del pacchetto da
$1,200


Visita dal medico
Prezzo su richiesta




Il medico è un oncologo radioterapista altamente qualificato con vasta esperienza nel trattamento di una vasta gamma di tumori utilizzando tecniche avanzate di radioterapia. Ha una comprovata esperienza nel migliorare i risultati dei pazienti attraverso piani di trattamento personalizzati e tecnologia all'avanguardia.<\/p>
Certificato in oncologia radioterapica, il medico ha contribuito a numerosi studi clinici e di ricerca, migliorando la comprensione e l'efficacia dei trattamenti radioterapici. È impegnato nell'apprendimento continuo e ha partecipato a numerose conferenze internazionali per rimanere aggiornato sugli ultimi sviluppi nel campo.<\/p>
Prezzo del pacchetto da
$1,200




Il medico è un oncologo specializzato nel trattamento dei tumori al seno, ai polmoni e gastrointestinali. Attualmente, il medico pratica presso l'Ospedale Universitario Istinye Liv.
Con una carriera che si estende su molteplici istituzioni prestigiose, il medico ha servito come Specialista in Medicina Interna presso l'Ospedale Statale di Malatya, medico presso la Clinica Oncologica di Ankara e membro del Dipartimento di Oncologia presso l'Ospedale Regionale di Formazione e Ricerca di Erzurum.
Il medico si è laureato presso la Facoltà di Medicina dell'Università di Selcuk e ha ottenuto il titolo di Professore Associato nel 2016.
Visita dal medico
Prezzo su richiesta
10 persone hanno richiesto un preventivo lo scorso mese




Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology
Education:
Professional Experience:
Clinical Trials, Courses, Certifications:
Clinical Trials:
Courses:
Certifications:
Memberships:
Visita dal medico
Prezzo su richiesta



PROFESSIONAL EXPERIENCE
2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine
2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine
06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine
10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship
2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship
2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist
2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.
EDUCATION
2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey
2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey
2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey
2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey
2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.
2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey
INTERNATIONAL CLINICAL TRIALS:
1. Astefania - ROCHE
2. PFİZER
3. RECITE - AMGEN
4. NAVIGATE - BAYER
5. RUBY - Tesaro (PRA)
6. ENGOT-ov43/GOG-3036 - MSD
7. ASTRA ZENECA
8. ROSY-O - ASTRA ZENECA
INTERNATIONAL PUBLICATIONS
I. Published journal articles indexed by SCI, SSCI, and AHCI
Weekly Paclitaxel in Classic Kaposi Sarcoma
Carboplatin Desensitization in Ovarian Carcinoma
High-Dose Chemotherapy for Ewing’s Sarcoma
Multidrug Refractory TFE3(+) Renal Cell Carcinoma
Crizotinib Efficacy in NSCLC with MET Alterations
Clinicopathological Features in ALK Mutant NSCLC
PSMA-Based Tumor Burden in Prostate Cancer
Atezolizumab in Metastatic Urothelial Carcinoma
Pulmonary Sarcomatoid Carcinoma
Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma
Atezolizumab with Chemotherapy in Small Cell Lung Cancer
FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer
Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients
Real-Life Efficacy of Osimertinib in Advanced NSCLC
ALK-Positive Cells Percentage and Alectinib Efficacy
Real-World Data on Alectinib in ALK-Positive NSCLC
Prognostic Factors in Metastatic RCC with T790M Mutation
FLOT Regimen in Metastatic Gastric Cancer
Desensitization Protocol in Lenalidomide Hypersensitivity Reactions
Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity
Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors
Subsequent Treatments in Hormone-Positive Breast Cancer Progression
Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer
Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer
Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer
Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer
Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients
Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients
Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases
FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer
Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer
Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma
Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma
Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)
Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)
Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49
Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4
Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.
Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology
Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)
Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)
Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)
Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)
Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye
Thesis:
Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)
International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)
Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination
Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer
Efficacy of temozolomide in pretreated patients with metastatic sarcoma
Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors
Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Visita dal medico
Prezzo su richiesta





Education
Ondokuz Mayıs University Faculty of Medicine (1991)
KTÜ Faculty of Medicine Farabi Hospital (Specialization.1998)
Istanbul University Çapa Faculty of Medicine (Laparoscopic Surgery Training, 2002)
Istanbul University Çapa Faculty of Medicine (Laparoscopic Antireflux Surgery Training, 2006)
Istanbul University Cerrahpaşa Faculty of Medicine (General Surgery Clinic Advance Laparoscopic Surgery, Laparoscopic Bariatric Surgery, Morbid Obesity and Oncological Cancer Surgery Training, 2010i)
Visita dal medico
Prezzo su richiesta



Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.
Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.
Visita dal medico
Prezzo su richiesta


Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.
Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).
Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).
Visita dal medico
Prezzo su richiesta



Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.
He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.
Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.
Visita dal medico
Prezzo su richiesta





Visita dal medico
Prezzo su richiesta


Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).
He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.
Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.
Visita dal medico
Prezzo su richiesta



Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).
She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).
Visita dal medico
Prezzo su richiesta





Specializations
Cancer Surgery
Pancreatic Surgery
Bile Duct Surgery
Bariatric Metabolic Surgery
Oncological Surgery
Breast Surgery
Gastric cancer
Colon cancer
Thyroid Cancer
Obesity Surgery
Diabetes Surgeries
Visita dal medico
Prezzo su richiesta





NUTRITION AND DIET SPECIALIST
Ezgi Sevic graduated from Hacettepe University, Department of Nutrition and Dietetic as Honor Student. During her education, she conducted studies on “'The Effect of Hedonic Eating Behavior on Obesity', 'Total Parenteral Nutrition in Children' and 'The Relationship Between Insulin Resistance and Obesity'.” During her education, she took part in the field in studies on determining the nutritional status of the society. She worked as intern dietitian in Hospitals of Hacettepe University (Oncology Hospital, Adults Hospital, İhsan Doğramacı Child Hospital), Dışkapı Yıldırım Beyazıt Training and Research Hospital and many Community Health Centres.
She worked in Izmir Private Ekol Hospital. She successfully completed the 'Bariatric Nutrition Course' and the 'Innovations in Obesity Course'. She has participated in many training and seminar programs in her field.
Interests: Post- Metabolic and Bariatric Surgery Nutrition, the Nutrition in Chronicle Diseases, Nutrition in Individuals with Diabetes, Nutrition in Cancer, Nutrition in Congenital Metabolic Diseases, Food Intolerances, Body Weight Control, Child and Adolescent Nutrition, Nutrition in Old Age, Nutrition in Pregnancy and Lactation.
Dietit. Ezgi Sevic knows advanced English.
Visita dal medico
Prezzo su richiesta



Visita dal medico
Prezzo su richiesta




Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015
MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022
Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)
Medical Intrests
Prezzo del pacchetto da
$10,000




Il medico ha completato la formazione di specializzazione in Oncologia Radioterapica presso la Facoltà di Medicina dell'Università di Marmara dal 2012 al 2016. Prima di questo, il medico ha completato una laurea in Medicina, insegnata in inglese, presso la stessa istituzione dal 2004 al 2011. Il medico ha una solida base nell'educazione medica, iniziando con l'istruzione superiore presso la Scuola Numero Sedici di Shirvan in Azerbaigian dal 1998 al 2004.<\/p>
Visita dal medico
Prezzo su richiesta




Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:
Breast Cancer
Prostate Cancer
Lung Cancer
Colorectal Cancer
Stomach Cancer
Ovarian Cancer
Visita dal medico
Prezzo su richiesta



Il medico è un rinomato Chirurgo Generale con oltre 20 anni di esperienza, specializzato in Chirurgia dell'Obesità e Metabolica, Chirurgia Laparoscopica Avanzata, Chirurgia della Tiroide e Paratiroide, e Chirurgia Oncologica.<\/p>
Si è laureato presso la Facoltà di Medicina dell'Università di Erciyes nel 2000 e ha completato la formazione specialistica presso la Clinica di Chirurgia Generale dell'Ospedale Şişli Etfal nel 2009. Il medico ha pubblicato articoli su riviste internazionali con revisione paritaria.<\/p>
Visita dal medico
Prezzo su richiesta
Hai visualizzato 20 di 45 medici
Scegliere una clinica all'estero può essere stressante. Da Bookimed, con oltre 800.000 pazienti aiutati, comprendiamo le tue preoccupazioni. Sappiamo come trovare medici affidabili, le migliori opzioni per rapporto qualità-prezzo e soluzioni anche per casi complessi. Siamo qui per guidarti in ogni fase del tuo percorso sanitario.
Yan Matsiivskiy
Capo del team dei coordinatori medici
Oltre 4300+ viaggi assistiti di pazienti
3 anni su Bookimed
278 pazienti da Turkey hanno trovato il loro medico tramite noi questo mese
Quiz da 2 minuti
Dicci il tuo obiettivo, budget e tempistiche
Abbinamento umano + IA
Il nostro algoritmo trova le corrispondenze, il coordinatore verifica l'idoneità
Le tue opzioni pronte
Confronta prezzi, pacchetti, date. Chatta con il tuo coordinatore
Tante opzioni e non sai cosa scegliere?
Guida il tuo percorso di cura
Coordinatori personali medici qualificati






| Classifica | Medico | esperienza | Buona scelta per | Cosa li distingue | Clinica e posizione | Consulto |
|---|